Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation

Clinical and Experimental Immunology

Volumn 158, Issue SUPPL. 1, 2009, Pages 43-50

  Schwartz Albiez, R ^a   Monteiro, R C ^b   Rodriguez, M ^c   Binder, C J ^d,e   Shoenfeld, Y ^f,g  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INSERM   (France)

^c MAYO GRADUATE SCHOOL   (United States)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f SHEBA MEDICAL CENTER   (Israel)

^g TEL AVIV UNIVERSITY   (Israel)

Author keywords

Atherosclerosis; Cancer; IgA; Multiple sclerosis; Oxidation specific epitopes

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M ANTIBODY; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNITY; CANCER THERAPY; DRUG BINDING; GLOMERULONEPHRITIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; MULTIPLE SCLEROSIS; NEOPLASMS;

EID: 72149102130     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04026.x     Document Type: Review

References (44)

1. Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and diseases. Trends Immunol 2009 30 : 43 51.
2. Simon HU, Späth PJ. IVIG-mechanisms of action. Allergy 2003 58 : 543 552.
3. Kamijuku H, Nagata Y, Jiang X et al. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide which can induce cross-protection against influenza viruses. Mucosal Immunol 2008 1 : 208 218.
4. Cukrowska B, Sinkora J, Mandel L et al. Thymic B cells of pig fetuses and germ-free pigs spontaneously produce IgM, IgG and IgA: detection by Elispot method. Immunology 1996 87 : 487 492.
5. Schwartz-Albiez R, Laban S, Eichmueller S et al. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? Autoimmunity Rev 2008 7 : 491 495.
6. Pal S, Chatterjee M, Bhattecharya DK et al. Identification and purification of cytolytic antibodies directed against O-acetylated sialic acid in childhood acute lymphoblastic leukemia. Glycobiology 2000 10 : 539 549.
7. Monteiro R, van de Winkel JG. IgA Fc receptors. Ann Rev Immunol 2003 21 : 177 204.
8. Pasquier B, Launay P, Kanamaru Y et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005 22 : 31 42.
9. Bieber AJ, Warrington A, Pease LR, Rodriguez M. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci 2001 24 : 39 44.
10. Binder C, Chou J, Fogelstrand MY et al. Natural antibodies in murine atherosclerosis. Curr Drug Targets 2008 9 : 190 195.
11. Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumour spread in mice. Int Immunol 1999 11 : 1247 1251.
12. Shapiro S, Shoenfeld Y, Gilburd B et al. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002 95 : 2032 2037.
13. Sapir T, Blank M, Shoenfeld Y et al. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann NY Acad Sci 2005 1051 : 743 778.
14. Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol 2004 24 : 107 114.
15. Shoenfeld Y, Levy Y, Fishman P. Shrinkage of melanoma metastases following high doses intravenous immunoglobulin treatment. Isr Med Assoc J 2001 3 : 863.
16. Damianovich M, Solomon AS, Blank M, Shoenfeld Y. Attenuation of colon carcinoma tumour spread by intravenous immunoglobulin. Ann NY Acad Sci 2007 1110 : 567 577.
17. Schachter J, Katz U, Mahrer A et al. Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann NY Acad Sci 2007 1110 : 305 314.
18. Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol 2002 109 : 581 591.
19. Olas K, Butterweck H, Teschner W et al. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol 2005 140 : 478 490.
20. Pinheiro da Silva F, Aloulou M, Benhamou M, Monteiro RC. Inhibitory ITAMs: a matter of life and death. Trends Immunol 2008 29 : 366 373.
21. Kanamaru Y, Pfirsch S, Aloulou M et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol 2008 180 : 2669 2678.
22. Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol 1987 46 : 84 95.
23. Lang W, Rodriguez M, Lennon VA, Lampert PW. Demyelination and remyelination in murine viral encephalomyelitis. Ann NY Acad Sci 1984 436 : 98 102.
24. Warrington AE, Bieber AJ, Ciric B et al. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 2007 85 : 967 976.
25. Asakura K, Miller DJ, Murray K et al. Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes. J Neurosci Res 1996 43 : 273 281. (Pubitemid 26057424)
26. Asakura K, Miller DJ, Pease LR, Rodriguez M. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. J Neurosci 1998 18 : 7700 7708.
27. Warrington AE, Asakura K, Bieber AJ et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA 2000 97 : 6820 6825.
28. Hunter SF, Miller DJ, Rodriguez M. Monoclonal remyelination-promoting natural autoantibody SCH 94·03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis. J Neurol Sci 1997 150 : 103 113.
29. Pirko I, Ciric B, Gamez J et al. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J 2004 18 : 1577 1579.
30. Warrington AE, Bieber AJ, Van Keulen V et al. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol 2004 63 : 461 473.
31. McGavern DB, Murray PD, Rivera-Quinones C et al. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000 123 : 519 531.
32. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002 8 : 1218 1226.
33. Binder CJ, Shaw PX, Chang MK et al. The role of natural antibodies in atherogenesis. J Lipid Res 2005 46 : 1353 1363.
34. Palinski W, Hörkkö S, Miller E et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996 98 : 800 814.
35. Hörkkö S, Bird DA, Miller E et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999 103 : 117 128.
36. Chang MK, Binder CJ, Miller YI et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004 200 : 1359 1370.
37. Chang MK, Bergmark C, Laurila A et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA 1999 96 : 6353 6358.
38. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002 2 : 965 975.
39. Shaw PX, Hörkkö S, Chang MK et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. Clin Invest 2000 105 : 1731 1740.
40. Briles DE, Forman C, Hudak S, Claflin JL Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. Exp Med 1982 156 : 1177 1185.
41. Binder CJ, Hörkkö S, Dewan A et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidised LDL. Nat Med 2003 9 : 736 743.
42. Chou MY, Fogelstrand L, Hartvigsen K et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies. J Clin Invest 2009 119 : 1335 1349.
43. Imai Y, Kuba K, Neely GG et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008 133 : 235 249.
44. Faria-Neto JR, Chyu KY, Li X et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006 189 : 83 90.